, /PRNewswire/ -- the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with during to establish a world-class Rare Diseases Centre of Excellence (CoE) in . Leveraging advanced healthcare infrastructure and AstraZeneca's global expertise and experience in rare diseases management, the two entities will spearhead innovation to improve the lives of people and communities impacted by rare diseases, regionally and globally. In the presence of H.
E. , Chairman of DoH and , GCC and Pakistan Corporate Affairs Director at AstraZeneca, the MoU was signed by Dr. , the Executive Director of the Research and Innovation Centre at DoH and , Head of Government Affairs, GCC and at AstraZeneca.
Data suggests genetic and congenital disorders are more common in the Arab Gulf than in other industrialised countries, leading to a high socio-economic burden on patients, families and communities. This collaboration will help to address this burden by allowing the two entities to work together to establish a Rare Disease Centre of Excellence in the Emirate, serving as a hub for comprehensive diagnosis, treatment, follow-up, research education and patient care with a focus on haematology, neurology, and metabolic disorders. said: "We are proud to witness another collaboration with a prestigious partner during our participation at BIO 2024.
Our Emirate is already home to some of the world's most renowned global healthcare facilities, including four centres of .
